These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23960450)

  • 1. The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean.
    Kim JS; Ahn SM; Jung YK; Kwon OS; Kim YS; Choi DJ; Kim JH
    J Korean Med Sci; 2013 Aug; 28(8):1213-9. PubMed ID: 23960450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between ITPA rs1127354 polymorphisms and efficacy of antiviral treatment in Northeast Chinese CHC patients.
    Liu Z; Wang S; Qi W; Wang X; Sun D; Wang H; Zhang Y; Li Z; Zhu L; Zhao P; Guo H; Zhou C; Wang J
    Medicine (Baltimore); 2017 Jul; 96(29):e7554. PubMed ID: 28723780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy.
    Amjed S; Saleem HGM; Ullah S; Latif S; Shabana ; Jafar J; Waqar AB
    BMC Infect Dis; 2024 Mar; 24(1):301. PubMed ID: 38468199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.
    Thompson AJ; Santoro R; Piazzolla V; Clark PJ; Naggie S; Tillmann HL; Patel K; Muir AJ; Shianna KV; Mottola L; Petruzzellis D; Romano M; Sogari F; Facciorusso D; Goldstein DB; McHutchison JG; Mangia A
    Hepatology; 2011 Feb; 53(2):389-95. PubMed ID: 21274861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin.
    Miyamura T; Kanda T; Nakamoto S; Wu S; Jiang X; Arai M; Fujiwara K; Imazeki F; Yokosuka O
    Viruses; 2012 Aug; 4(8):1264-78. PubMed ID: 23012624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
    Kurosaki M; Tanaka Y; Tanaka K; Suzuki Y; Hoshioka Y; Tamaki N; Kato T; Yasui Y; Hosokawa T; Ueda K; Tsuchiya K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Matsuura K; Sugauchi F; Enomoto N; Nishida N; Tokunaga K; Mizokami M; Izumi N
    Antivir Ther; 2011; 16(5):685-94. PubMed ID: 21817190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
    Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
    Matsuura K; Tanaka Y; Watanabe T; Fujiwara K; Orito E; Kurosaki M; Izumi N; Sakamoto N; Enomoto N; Yatsuhashi H; Kusakabe A; Shinkai N; Nojiri S; Joh T; Mizokami M
    J Viral Hepat; 2014 Jul; 21(7):466-74. PubMed ID: 24750345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.
    Seto WK; Tsang OT; Liu K; Chan JM; Wong DK; Fung J; Lai CL; Yuen MF
    J Viral Hepat; 2013 Jul; 20(7):470-7. PubMed ID: 23730840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.
    Nomura H; Miyagi Y; Tanimoto H; Yamashita N; Ito K; Masaki N; Mizokami M
    J Gastroenterol Hepatol; 2012 Sep; 27(9):1461-6. PubMed ID: 22554247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.
    Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Okada K; Kainuma M; Kajiwara E; Takahashi K; Satoh T; Hayashi J
    J Viral Hepat; 2013 Dec; 20(12):838-46. PubMed ID: 24304453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
    Suzuki F; Suzuki Y; Akuta N; Sezaki H; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Chayama K; Kamatani N; Nakamura Y; Miyakawa Y; Kumada H
    Hepatology; 2011 Feb; 53(2):415-21. PubMed ID: 21246582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients.
    Heo NY; Lim YS; Lee W; Oh M; An J; Lee D; Shim JH; Kim KM; Lee HC; Lee YS; Suh DJ
    Clin Mol Hepatol; 2014 Jun; 20(2):177-84. PubMed ID: 25032184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort.
    Eskesen AN; Melum E; Moghaddam A; Bjøro K; Verbaan H; Ring-Larsen H; Dalgard O
    Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):890-6. PubMed ID: 22584257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.
    D'Avolio A; De Nicolò A; Cusato J; Ciancio A; Boglione L; Strona S; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G
    Antiviral Res; 2013 Oct; 100(1):114-9. PubMed ID: 23933495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.
    Scherzer TM; Stättermayer AF; Stauber R; Maieron A; Strasser M; Laferl H; Schwarzer R; Datz C; Rutter K; Beinhardt S; Steindl-Munda P; Hofer H; Ferenci P
    J Hepatol; 2013 Nov; 59(5):964-71. PubMed ID: 23850877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of ITPA gene polymorphisms with outcomes among chronic hepatitis C patients treated with Peg-interferon/ribavirin: A 5-year follow-up study.
    Liu Z; Wang Y; Li H; Wang X; Wang X; Xu X; Ma C; Wang J
    Medicine (Baltimore); 2023 Oct; 102(43):e35508. PubMed ID: 37904484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.
    Pineda-Tenor D; García-Álvarez M; Jiménez-Sousa MA; Vázquez-Morón S; Resino S
    J Transl Med; 2015 Oct; 13():320. PubMed ID: 26438033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?
    Veillon P; Fouchard-Hubert I; Larrey D; Dao MT; D'alteroche L; Boyer-Darrigand N; Picard N; Le Guillou-Guillemette H; Saulnier P; Ducancelle A; Loustaud-Ratti V; Lunel-Fabiani F
    J Interferon Cytokine Res; 2016 Mar; 36(3):204-14. PubMed ID: 26700738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphism of the inosine triphosphate pyrophosphatase gene predicts ribavirin-induced anemia in chronic hepatitis C patients.
    Nishimura T; Osaki R; Shioya M; Imaeda H; Aomatsu T; Takeuchi T; Okumura Y; Fujiyama Y; Andoh A
    Mol Med Rep; 2012 Feb; 5(2):517-20. PubMed ID: 22052220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.